Latest Brokerage News

Arafura Rare Earths Limited has announced a Share Purchase Plan (SPP) targeting $50 million to support its Nolans Project, subject to shareholder approval. The offer allows eligible shareholders to subscribe for shares at a discounted price, with potential oversubscriptions up to $20 million.

Aeris Resources has launched a Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy shares at a discounted price, aiming to raise up to $10 million for working capital.

Javelin Minerals has initiated a significant capital consolidation, reducing its share count by a factor of 31, and is introducing a facility to help small shareholders sell untradeable parcels post-consolidation.

Barton Gold Holdings reminds eligible shareholders that its Share Purchase Plan (SPP) closes on 6 November 2025, offering shares at $1.25 each, the same price as a recent institutional placement. The SPP provides a cost-free opportunity for Australian and New Zealand investors to increase their stake ahead of the company’s next growth phase.

ANZ Group Holdings Limited has announced a 1.5% discount on shares acquired through its Dividend Reinvestment and Bonus Option Plans for the upcoming 2025 final dividend, signaling a subtle shift in shareholder incentives.

RMA Global Limited kicked off FY26 with a robust 21% increase in recurring revenue, driven by the rollout of Curated Social and a strategic pivot to target US brokerages exclusively. The company’s new Social Studio platform is gaining traction across the US, Australia, and New Zealand.

Triton Minerals progresses the sale of its Mozambique graphite assets despite ongoing legal challenges, while initiating exploration at its promising Aucu Gold-Copper Project.

HALO Technologies reports a 17% rise in quarterly revenue, driven by a surge in brokerage income and a strategic launch of Managed Funds in Australia, supported by a recent $3.9 million rights issue.

Aeris Resources has secured $80 million through an institutional placement and launched a $10 million share purchase plan, aiming to repay debt and accelerate key exploration projects.

TT Investments has extended its unconditional takeover offer for 360 Capital Group securities to 13 November 2025, maintaining a substantial premium and signaling potential strategic shifts post-acquisition.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Conico Ltd updates shareholders on a significant capital raising expansion, including a share consolidation and converting loan conversions to fund exploration at Mount Thirsty.